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KEY POINTS 
 
Question: Which factors are associated with aggressive SCC in OTR?  
Findings: Aggressive SCC were preferentially localized on the face (66.7%). 41.2% of the 
tumors were poorly-differentiated with a median tumor diameter of 18mm and tumor depth of 
6.2mm.  
Meaning: Anatomical site, differentiation, tumor diameter, tumor depth and perineural 
invasion are important risk factors in aggressive SCC in OTR.  
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ABSTRACT 
 
Importance: Squamous cell carcinoma (SCC) is the most frequent malignancy found in solid 
organ transplant recipients (OTR) and is associated with a more aggressive behavior and a 
higher risk of metastasis and death than in the general population.  
Objective: We aimed to report clinicopathological features and to identify factors associated 
with aggressive SCC in OTR.  
Methods: This retrospective multicentric case series included 51 patients after solid organ 
transplantation with aggressive SCC defined by nodal or distant metastasis or death by local 
progression of primary SCC. 
Results: 84.3% of the 51 solid organ transplant recipients who developed an aggressive 
SCC were men, with a median age of 51 years at time of transplantation and 62 years at 
time of diagnosis of aggressive SCC. The distribution of aggressive SCC was preferentially 
on the face (66.7%) and scalp (11.8%), followed by the upper extremities (11.8%). 41.2% of 
the tumors were poorly-differentiated with a median tumor diameter of 18 mm and tumor 
depth of 6.2 mm. Perineural invasion was present in 39.2%, while 45.1% showed a local 
recurrence. 5-year overall survival rate was 23%, while 5-year disease-specific survival was 
30.5%.  
Conclusion: Taken together, our case series confirms anatomical site, differentiation, tumor 
diameter, tumor depth and perineural invasion as important risk factors in aggressive SCC in 
OTR. Trial registration: clinicalTrials.gov, ID Number NCT02095912. 
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INTRODUCTION 
 
Cutaneous squamous cell carcinoma (SCC) is a malignant neoplasm deriving from 
epidermal keratinocytes. In the general population it is the second most common form of 
keratinoyte carcinoma (KC) after basal cell basal cell carcinoma { ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }} and in organ transplant recipients (OTR) it is the most common skin 
cancer { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. Previous studies report a risk for nodal 
metastasis of 1.9-4% and for disease-specific death (DSD) of 1.5-2.1% in the general 
population { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}.  
 
The number of solid organ transplants and the long-term survival in organ transplant 
recipients have increased over the last decades as a result of progress in both surgical 
techniques and drug-induced immunosuppression { ADDIN EN.CITE 
<EndNote><Cite><Author>Lechler</Author><Year>2005</Year><IDText>Organ 
transplantation--how much of the promise has been 
realized?</IDText><DisplayText>(16)</DisplayText><record><dates><pub-
dates><date>Jun</date></pub-
dates><year>2005</year></dates><keywords><keyword>Animals</keyword><keyword>B-
Lymphocytes</keyword><keyword>Graft Rejection/immunology</keyword><keyword>Graft 
Survival</keyword><keyword>Humans</keyword><keyword>Immunologic 
Memory</keyword><keyword>Immunosuppressive Agents/therapeutic 
use</keyword><keyword>*Organ Transplantation</keyword><keyword>T-
Lymphocytes</keyword><keyword>Transplants/supply &amp; 
distribution</keyword></keywords><isbn>1078-8956 (Print)&#xD;1078-
8956</isbn><titles><title>Organ transplantation--how much of the promise has been 
realized?</title><secondary-title>Nat Med</secondary-title><alt-title>Nature medicine</alt-
title></titles><pages>605-
13</pages><number>6</number><contributors><authors><author>Lechler, R. 
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I.</author><author>Sykes, M.</author><author>Thomson, A. W.</author><author>Turka, L. 
A.</author></authors></contributors><edition>2005/06/07</edition><language>eng</langua
ge><added-date format="utc">1455269548</added-date><ref-type name="Journal 
Article">17</ref-type><auth-address>Guy&apos;s King&apos;s and St. Thomas&apos;s 
Medical School, King&apos;s College London, Hodgkin Building, Guy&apos;s Campus, 
London SE1 9RT, UK.</auth-address><remote-database-provider>NLM</remote-database-
provider><rec-number>153</rec-number><last-updated-date 
format="utc">1455269548</last-updated-date><accession-num>15937473</accession-
num><electronic-resource-num>10.1038/nm1251</electronic-resource-
num><volume>11</volume></record></Cite></EndNote>}. Notwithstanding the clear 
benefits of successful allograft transplantation, organ transplant recipients experience 
important side effects from the long term immunosuppressive medication, including a 10-fold 
increased risk for malignancies overall { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. In 
particular, OTR have a 65-250 -fold higher incidence of SCC compared to the non-
transplanted population. After transplantation, 20 to 75 percent of OTR are affected by at 
least one SCC within 20 years. After a first invasive SCC, multiple subsequent SCC will 
develop in 60-80% of these patients within 3 years { ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }}. The risk of SCC increases over time, with the incidence increasing to 40-
60% at 20 years post-transplant { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}.  
Cutaneous SCC is also associated with a more aggressive behavior and a higher risk of 
metastasis and death in OTR than in the general population { ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }}. The metastaric rate in OTR is reported to be 5-8% { ADDIN EN.CITE { 
ADDIN EN.CITE.DATA }}.   
 
In addition to immunosuppression and time from transplantation, the factors for the 
development of SCC in OTRs are similar to those found in the general population, namely 
male gender, age, cumulative ultraviolet radiation exposure and fair skin { ADDIN EN.CITE { 
ADDIN EN.CITE.DATA }}.  
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While the majority of SCC will be successfully treated, some show a very aggressive clinical 
course. Currently, the distinction between the many SCC cured without sequelae and the few 
SCC with an aggressive course can be hard to make at diagnosis. The objective of the 
present study based on a European OTR case series is to report clinicopathological features 
of behavior aggressive SCC and to identify factors which are associated with an aggressive 
development of SCC in OTR 
 
METHODS 
Clinical and histological data were retrospectively collected from 5 centers: Brussels 
(Belgium), Barcelona (Spain), Leiden (Netherlands), London (United Kingdom) and Zurich 
(Switzerland) within the Skin Care in Organ Transplant Patients, Europe (SCOPE) Network. 
The study protocol was approved by the Ethics Committee of Zurich, Switzerland.  
Inclusion criteria were patients who underwent a solid organ transplantation and developed 
an aggressive SCC including nodal or distant metastasis or death by local progression of 
primary SCC. All patient identifiers were coded to assure patient anonymity. Exclusion 
criteria were the absence of an aggressive SCC, mucosal head and neck SCC or missing 
data. All participating centres were able to identify and retrieve organ transplant recipients 
with aggressive SCC from their archives. Standard questionnaires were completed between 
July 2005 and January 2015. Patients were followed up from the data of first transplantation 
to date of death or the last dermatologist visit. Skin photo type classification was not 
recorded because of incomplete data at the time of inclusion. Data were obtained from the 
hospital database including patient's charts and pathology reports.  
Disease-specific death was considered to have occurred if the treatment team documented 
that the patient died of a specific SCC or of complications that directly arose from SCC. Non-
disease-specific death was considered to have occurred in patients who developed nodal or 
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distant metastasis or a local, treatment-refractory tumor but died because of other causes 
(for example cardiac arrest).  
 
STATISTICAL ANALYSIS 
Clinical characteristics were summarized with the use of descriptive statistics and frequency 
tabulation. Overall survival, disease-specific survival, progression-free survival and time from 
metastasis to death were analyzed by the Kaplan-Meier method. IBM SPSS statistic software 
(version 23.0.) was used for statistical analysis. 
 
RESULTS 
 
The majority of the 51 solid organ transplant recipients who developed an aggressive SCC 
were male (84.3%) and kidney transplanted (78.4%). Median age at diagnosis was 62 years 
(range 36-77y). Three patients (5.8%) underwent combined kidney/pancreas transplantation 
and 1 patient had a liver and lung transplant. Ten patients (19.6%) underwent 2 
transplantations because of organ failure. Full characteristics of the study population are 
summarized in Table 1. 
 
The most common primary site for SCC was the face. The median diameter of aggressive 
SCC was 18.0 mm (range 4-64 mm) with a median depth of invasion of 6.2 mm (range 1-20 
mm). 21 (41.2%) of the tumors were histologically classified as poorly-differentiated and 
perineural invasion was identified in 39.2% of the SCC. The local recurrence rate was 45.1%. 
Tumour characteristics are listed in detail in Table 2. Figure 1a - d show overall survival, 
disease-specific survival, progression-free survival and time from metastasis to death overall 
by Kaplan Meier analysis. Briefly summarized, the graphs show that mortality was mostly 
{ PAGE   \* MERGEFORMAT } 
 
due to aggressive SCC. Almost all SCC showed progression within two years from 
diagnosis.  
 
DISCUSSION 
 
 
Patient characteristics 
The majority of our OTR were male with a median age of 51 years at time of transplantation 
and median 62 years old at diagnosis of aggressive SCC. This is in agreement with the 
findings of Pinho et al, who reported KC with a median age of 54.5 years at transplantation 
and 61.9 years at diagnosis of aggressive SCC. In contrast to our data, there was no 
difference in terms of gender in their study { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. In 
a study by Lott et al, SCC in OTR occurred earlier at the age of 57 years compared to the 
immunocompetent patients who developed SCC at a median age of 67 years { ADDIN 
EN.CITE <EndNote><Cite><Author>Lott</Author><Year>2010</Year><IDText>Aggressive 
behavior of nonmelanotic skin cancers in solid organ transplant 
recipients</IDText><DisplayText>(22)</DisplayText><record><dates><pub-
dates><date>Sep 27</date></pub-
dates><year>2010</year></dates><keywords><keyword>Adolescent</keyword><keyword>
Adult</keyword><keyword>Age 
Factors</keyword><keyword>Aged</keyword><keyword>Aggression/*psychology</keyword
><keyword>Carcinoma, Basal 
Cell/epidemiology/psychology</keyword><keyword>Carcinoma, Squamous 
Cell/epidemiology/psychology</keyword><keyword>Child</keyword><keyword>Humans</ke
yword><keyword>Intensive Care Units/statistics &amp; numerical 
data</keyword><keyword>Middle Aged</keyword><keyword>Organ 
Transplantation/adverse effects/*psychology</keyword><keyword>Skin 
Neoplasms/epidemiology/*psychology</keyword></keywords><isbn>0041-
1337</isbn><titles><title>Aggressive behavior of nonmelanotic skin cancers in solid organ 
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transplant recipients</title><secondary-title>Transplantation</secondary-title><alt-
title>Transplantation</alt-title></titles><pages>683-
7</pages><number>6</number><contributors><authors><author>Lott, D. 
G.</author><author>Manz, R.</author><author>Koch, C.</author><author>Lorenz, R. 
R.</author></authors></contributors><edition>2010/09/03</edition><language>eng</langua
ge><added-date format="utc">1421242615</added-date><ref-type name="Journal 
Article">17</ref-type><auth-address>Cleveland Clinic Head and Neck Institute, Cleveland, 
OH 44195, USA. lottd@ccf.org</auth-address><remote-database-provider>NLM</remote-
database-provider><rec-number>129</rec-number><last-updated-date 
format="utc">1421242615</last-updated-date><accession-num>20808266</accession-
num><electronic-resource-num>10.1097/TP.0b013e3181ec7228</electronic-resource-
num><volume>90</volume></record></Cite></EndNote>}.  
In summary, while our case series was not selected in a randomized fashion, our patient 
characteristics suggest our series to be quite typical for OTR. 
 
Tumor characteristics 
The body site for aggressive SCC in our study was preferentially on the face and scalp, 
followed by the upper extremities. Rabinovics et al similarly report a high number of SCC in 
the head and neck region with a 24% incidence of aggressive (local recurrence, nodal or 
distant metastasis) head and neck SCC in OTR, compared to other aggressive malignancies 
occurring on the head and neck  { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. Pinho et al 
found NMSC on UV-exposed sites for 83% of SCC and 87% of BCC { ADDIN EN.CITE { 
ADDIN EN.CITE.DATA }}. 
Most tumors in our series were poorly or moderately differentiated. The presence of poor 
differentiation indicates a poorer prognosis: Brantsch et al shows a 3-fold higher risk for local 
recurrence and a 2-fold higher risk for metastasis compared with well-differentiated SCC { 
ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. Mullen et al show a 2.9-fold higher risk of 
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metastasis or death in poorly differentiated tumors compared to well or moderately 
differentiated tumors { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}.  
Our median tumor diameter was 18 mm (range 4-64 mm). This is slightly less than the 
Swedish cohort in which aggressive SCC were 20 mm in diameter or greater { ADDIN 
EN.CITE { ADDIN EN.CITE.DATA }}. Based on a meta-analysis by Thompson et al tumor 
diameter > 2 cm is the risk factor most highly associated with disease-specific death and a 
19-fold higher risk of death from SCC compared to tumors < 2 cm { ADDIN EN.CITE { 
ADDIN EN.CITE.DATA }}.  
The median tumor thickness in our study population was 6.2 mm. This risk factor is highly 
associated with recurrence and metastasis, with tumor thickness > 2 mm having a 10-fold 
higher risk of local recurrence and 11-fold higher risk of metastasis { ADDIN EN.CITE { 
ADDIN EN.CITE.DATA }}.  In a prospective study of Breuninger et al, depth greater than 4 
mm was linked to a metastasis rate of 9%, increasing to a metastasis rate of 16% for a tumor 
thickness of 6 mm and more { ADDIN EN.CITE 
<EndNote><Cite><Author>Breuninger</Author><Year>2012</Year><IDText>Comparison 
and evaluation of the current staging of cutaneous 
carcinomas</IDText><DisplayText>(34)</DisplayText><record><dates><pub-
dates><date>Aug</date></pub-
dates><year>2012</year></dates><keywords><keyword>Carcinoma/*classification/*patholo
gy</keyword><keyword>Germany</keyword><keyword>Humans</keyword><keyword>Inter
nationality</keyword><keyword>Neoplasm 
Staging/*methods/*standards</keyword><keyword>*Practice Guidelines as 
Topic</keyword><keyword>Reproducibility of Results</keyword><keyword>Sensitivity and 
Specificity</keyword><keyword>Skin 
Neoplasms/*classification/*pathology</keyword></keywords><isbn>1610-
0379</isbn><titles><title>Comparison and evaluation of the current staging of cutaneous 
carcinomas</title><secondary-title>J Dtsch Dermatol Ges</secondary-title><alt-title>Journal 
der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of 
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Dermatology : JDDG</alt-title></titles><pages>579-
86</pages><number>8</number><contributors><authors><author>Breuninger, 
H.</author><author>Brantsch, K.</author><author>Eigentler, T.</author><author>Hafner, 
H. 
M.</author></authors></contributors><edition>2012/03/13</edition><language>eng&#xD;ge
r</language><added-date format="utc">1515337485</added-date><ref-type name="Journal 
Article">17</ref-type><auth-address>Department of Dermatology, Tubingen University 
Hospital, Germany. helmut.breuninger@med.unituebingen.de</auth-address><remote-
database-provider>NLM</remote-database-provider><rec-number>189</rec-number><last-
updated-date format="utc">1515337485</last-updated-date><accession-
num>22405579</accession-num><electronic-resource-num>10.1111/j.1610-
0387.2012.07896.x</electronic-resource-
num><volume>10</volume></record></Cite></EndNote>}.  
Perineural invasion (39%) and local recurrence (45%) were frequent, but will have been 
selected for in a cohort of aggressive SCC. In the general population, perineural invasion is 
rather rare with an incidence of 2.5-5% for primary SCCs and is associated with a 4- to 5-fold 
increased risk of nodal metastasis and death due to SCC { ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }}. Local recurrence is reported to occur in 7-16% of all SCC and is more 
frequent when there is perineural invasion { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}.  
The most common location of metastasis in our OTR were lymph nodes including parotid 
gland and skin. Lindelöf et al demonstrated that all lethal SCC (7 of 544 SCC in a cohort of 
5931 OTR) were located on the head, and that the parotid gland was the principal site for 
metastasis { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. A retrospective study by Lott et al 
found a 3.5 higher risk for OTR to develop lymph node metastasis compared to the tumors in 
the immunocompetent control group { ADDIN EN.CITE 
<EndNote><Cite><Author>Lott</Author><Year>2010</Year><IDText>Aggressive behavior 
of nonmelanotic skin cancers in solid organ transplant 
recipients</IDText><DisplayText>(22)</DisplayText><record><dates><pub-
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dates><date>Sep 27</date></pub-
dates><year>2010</year></dates><keywords><keyword>Adolescent</keyword><keyword>
Adult</keyword><keyword>Age 
Factors</keyword><keyword>Aged</keyword><keyword>Aggression/*psychology</keyword
><keyword>Carcinoma, Basal 
Cell/epidemiology/psychology</keyword><keyword>Carcinoma, Squamous 
Cell/epidemiology/psychology</keyword><keyword>Child</keyword><keyword>Humans</ke
yword><keyword>Intensive Care Units/statistics &amp; numerical 
data</keyword><keyword>Middle Aged</keyword><keyword>Organ 
Transplantation/adverse effects/*psychology</keyword><keyword>Skin 
Neoplasms/epidemiology/*psychology</keyword></keywords><isbn>0041-
1337</isbn><titles><title>Aggressive behavior of nonmelanotic skin cancers in solid organ 
transplant recipients</title><secondary-title>Transplantation</secondary-title><alt-
title>Transplantation</alt-title></titles><pages>683-
7</pages><number>6</number><contributors><authors><author>Lott, D. 
G.</author><author>Manz, R.</author><author>Koch, C.</author><author>Lorenz, R. 
R.</author></authors></contributors><edition>2010/09/03</edition><language>eng</langua
ge><added-date format="utc">1421242615</added-date><ref-type name="Journal 
Article">17</ref-type><auth-address>Cleveland Clinic Head and Neck Institute, Cleveland, 
OH 44195, USA. lottd@ccf.org</auth-address><remote-database-provider>NLM</remote-
database-provider><rec-number>129</rec-number><last-updated-date 
format="utc">1421242615</last-updated-date><accession-num>20808266</accession-
num><electronic-resource-num>10.1097/TP.0b013e3181ec7228</electronic-resource-
num><volume>90</volume></record></Cite></EndNote>}.  
In summary, our case series confirms anatomical site, differentiation, tumor diameter, 
thickness and perineural invasion as important risk factors in aggressive SCC in OTR. 
 
Survival 
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Our study demonstrated a poor prognosis of aggressive SCC with a 5-year overall survival 
rate of 23% and a 5-year disease-specific survival of 30.5%. Rabinovics et al showed a 5-
year survival of 67.7% and 10-year survival of 40% in patients with SCC, including however 
non-aggressive SCC { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. Lott et al reported a 3-
year disease-specific survival of 56% for metastatic SCC in OTR { ADDIN EN.CITE 
<EndNote><Cite><Author>Lott</Author><Year>2010</Year><IDText>Aggressive behavior 
of nonmelanotic skin cancers in solid organ transplant 
recipients</IDText><DisplayText>(22)</DisplayText><record><dates><pub-
dates><date>Sep 27</date></pub-
dates><year>2010</year></dates><keywords><keyword>Adolescent</keyword><keyword>
Adult</keyword><keyword>Age 
Factors</keyword><keyword>Aged</keyword><keyword>Aggression/*psychology</keyword
><keyword>Carcinoma, Basal 
Cell/epidemiology/psychology</keyword><keyword>Carcinoma, Squamous 
Cell/epidemiology/psychology</keyword><keyword>Child</keyword><keyword>Humans</ke
yword><keyword>Intensive Care Units/statistics &amp; numerical 
data</keyword><keyword>Middle Aged</keyword><keyword>Organ 
Transplantation/adverse effects/*psychology</keyword><keyword>Skin 
Neoplasms/epidemiology/*psychology</keyword></keywords><isbn>0041-
1337</isbn><titles><title>Aggressive behavior of nonmelanotic skin cancers in solid organ 
transplant recipients</title><secondary-title>Transplantation</secondary-title><alt-
title>Transplantation</alt-title></titles><pages>683-
7</pages><number>6</number><contributors><authors><author>Lott, D. 
G.</author><author>Manz, R.</author><author>Koch, C.</author><author>Lorenz, R. 
R.</author></authors></contributors><edition>2010/09/03</edition><language>eng</langua
ge><added-date format="utc">1421242615</added-date><ref-type name="Journal 
Article">17</ref-type><auth-address>Cleveland Clinic Head and Neck Institute, Cleveland, 
OH 44195, USA. lottd@ccf.org</auth-address><remote-database-provider>NLM</remote-
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database-provider><rec-number>129</rec-number><last-updated-date 
format="utc">1421242615</last-updated-date><accession-num>20808266</accession-
num><electronic-resource-num>10.1097/TP.0b013e3181ec7228</electronic-resource-
num><volume>90</volume></record></Cite></EndNote>}. A Texan study by Mullen et al 
showed a 5-year overall survival rate of 35% and a 5-year disease-specific survival of 50% in 
patients with aggressive SCC of the trunk or extremities { ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }}. In summary, our case series in OTR shows an unfavorable survival of 
primary SCC with aggressive features, comparable to other reports. 
 
Limitations  
This study is limited by its retrospective design, the limited number of cases and number of 
contributing centers. There is an implict bias in selecting tumors with a poor outcome 
(recurrence, metastasis, death) towards clinical and pathological factors known to be 
associated with poor outcomes, such as perineural invasion. Another limitation is the lack of 
a control group (OTR without development of aggressive SCC).  Data on ethnicity, skin type 
and sun exposure were not available. 
 
Conclusion 
Taken together, our case series confirms anatomical site, differentiation, tumor diameter, 
tumor depth and perineural invasion as important risk factors in aggressive SCC in OTR. We 
demonstrated a poor prognosis of aggressive SCC.  
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  n = 51 
Sex 
     Female 
     Male 
 n (%) 
     8 (15.7) 
   43 (84.3) 
Age 
     At time of transplantation 
     At diagnosis of aggressive SCC 
Median (Range), [years] 
   51 (19-71) 
   62 (36-77) 
Transplanted organ 
     Kidney 
     Heart 
     Liver 
     Lung 
     Kidney and pancreas 
     Liver and lung 
n (%) 
   40 (78.4) 
     2   (3.9) 
     1   (2.0) 
     4   (7.8) 
     3   (5.9) 
     1   (2.0) 
Survival status at last follow-up 
     Alive 
     Death due to SCC 
     Death due to other causes 
n (%) 
     7   (13.7) 
   32   (62.7) 
   12   (23.5) 
 
Table 1: Patient characteristics 
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 n (%), total 51 
Location of aggressive SCC 
     Scalp 
     Face 
     Neck 
     Trunk 
     Arm or hand 
     Genitalia 
 
     6   (11.8) 
   34   (66.7) 
     1     (2.0) 
     2     (3.9) 
     6   (11.8) 
     2     (3.9) 
Histological Classification of SCC 
     Well-differentiated 
     Moderately-differentiated 
     Poorly-differentiated 
     Spindle cell morphology 
     Desmoplastic 
 
   10   (19.6) 
   15   (29.4) 
   21   (41.2) 
     2     (3.9) 
     3     (5.9) 
Primary tumor 
     Diameter of SCC  
     Depth of invasion 
     Tumor-free margins on histology 
Median (Range), [mm]      Total (Missing) 
   18.0   (4-64)                          50   (1) 
     6.2   (1-20)                          48   (3)            
     2.0   (0-15)                          38 (13) 
Clark level of Invasion 
     Level I  
     Level II  
     Level III  
     Level IV  
     Level V  
     Missing data 
 
     1     (2.0) 
     1     (2.0) 
     0        (0) 
   14   (27.5) 
   33   (64.7) 
     2     (3.9) 
Perineural Invasion 
     Absent 
     Present 
     Missing data 
 
   30   (58.8) 
   20   (39.2) 
     1     (2.0) 
Local recurrence 
     Absent 
     Present 
     Missing data 
 
   21   (41.2) 
   23   (45.1) 
     7   (13.7) 
Metastasis site 
     No Metastasis 
     Lymph Nodes 
     Parotid Gland 
     Liver 
     Lung 
     Brain 
     Bone 
     Skin 
     Muscle 
     Intraorbital 
 
     6   (11.8) 
   30   (58.8) 
   10   (19.6) 
     2     (3.9) 
     6   (11.8) 
     4     (7.8) 
     7   (13.7) 
   11   (21.6) 
     1     (1.9) 
     1     (1.9) 
 
Table 2: Tumor characteristics 
 
An aggressive SCC was defined by regional metastasis (lymph nodes, parotid gland), distant 
metastasis including liver, lung, brain, bone etc., or a local, therapy-resistant progression of 
primary SCC.  
Clark level I (confined to epidermis), level II (penetrating papillary dermis), level III (filling the 
papillary dermis), level IV (extending into reticular dermis), level V (invasion of subcutis). 
Metastasis location was counted for every patient, while some had multiple organ 
metastasis. 
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Figure 1a: Overall survival  
 
The graph shows overall survival by Kaplan Meier analysis. 50% overall survival was 
reached at 28 months with an 95 % confidence interval from 21.3 to 34.7. 5-year overall 
survival was 23 % (SD ± 6.4 %), while 10-year survival was 11.3% (SD ± 5.5 %). 
SD: standard deviation. 
 
 
 
{ PAGE   \* MERGEFORMAT } 
 
 
 
Figure 1b: Disease-specific survival 
The graph shows disease-specific survival by Kaplan Meier analysis. 50% disease-specific 
survival was reached at 33 months with an 95 % confidence interval from 0.9 to 45.1.  
5-year disease-specific survival was 30.5 % (SD ± 7.6 %) and 10-year survival was 25.9% 
(SD ± 7.1 %).  
SD: standard deviation. 
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Figure 1c: Progression-free survival 
The graph shows progression-free survival by Kaplan Meier analysis. 5- and 10-year overall 
survival were 5 % with a 95 % confidence interval of 2.5 to 7.25 years (SD ± 1.3 %). 
SD: standard deviation. 
 
 
{ PAGE   \* MERGEFORMAT } 
 
 
 
Figure 1d: Time from metastasis to death overall 
The graph shows overall time from metastasis to death by Kaplan Meier analysis. The 
median time from metastasis to death was 12 months with a 95 % confidence interval from 
3.8 to 20.2. 
 
